共 50 条
FGF23-Associated Tumor-Induced Osteomalacia in a Patient With Small Cell Carcinoma: A Case Report and Regulatory Mechanism Study
被引:20
|作者:
Sauder, Adrienne
[1
]
Wiernek, Szymon
[2
]
Dai, Xumin
[2
]
Pereira, Renata
[3
]
Yudd, Michael
[4
]
Patel, Charvi
[1
]
Golden, Andrew
[1
]
Ahmed, Shahida
[4
]
Choe, Jin
[4
]
Chang, Victor
[4
]
Sender, Slawomir
[4
]
Cai, Donghong
[4
]
机构:
[1] Rutgers New Jersey Med Sch, Newark, NJ USA
[2] Univ N Carolina, Chapel Hill, NC USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] VA New Jersey Med Ctr, E Orange, NJ USA
关键词:
small cell carcinoma;
tumor-induced osteomalacia;
FGF23;
wnt signaling pathway;
OF-THE-LITERATURE;
ONCOGENIC OSTEOMALACIA;
MESENCHYMAL TUMORS;
PHOSPHATE;
CANCER;
HYPOPHOSPHATEMIA;
LIVER;
FGF23;
D O I:
10.1177/1066896915617828
中图分类号:
R36 [病理学];
学科分类号:
100104 ;
摘要:
Tumor-induced osteomalacia (TIO) is typically caused by phosphaturic mesenchymal tumor (PMT) that secretes the phosphaturic hormone, fibroblast growth factor-23 (FGF23), resulting in decreased phosphate reabsorption in kidneys, hypophosphatemia, and finally osteomalacia. Rare cases of malignant tumor manifesting with TIO other than PMT had been reported, although in most of these reports, except one, circulating FGF23 levels were not evaluated and tissue expressing of FGF23 was not confirmed. In this article, we report a case of TIO in a patient with pulmonary small cell carcinoma with liver metastasis. The patient manifested with hypophosphatemia. His circulating level of FGF23 was markedly increased. The expression of FGF23 in tumor cells was confirmed. Furthermore, the regulatory mechanism of FGF23 in this patient was also investigated.
引用
收藏
页码:116 / 120
页数:5
相关论文